Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications January 10, 2024
First Patient Dosed in Ph 2b Trial of Samuraciclib + Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer December 19, 2023
Interim Data from Ph 1b Trial of Vepdegestrant in Combination with IBRANCE Announced December 11, 2023
Latest Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence in patients with early breast cancer; supports regulatory submissions December 11, 2023
Inavolisib combination reduces the risk of disease progression by 57% in people with advanced HR+ve, HER2-neg breast cancer with a PIK3CA mutation December 11, 2023
New Positive Interim Data from Dose Escalation and Ph 2 Expansion Cohorts of Zotatifin in ER+ Metastatic Breast Cancer Patients Announced December 11, 2023
U.S. FDA Fast Track Designation for Zotatifin in Combination with Fulvestrant and Abemaciclib for Treatment of ER+/HER2- Advanced Metastatic Breast Cancer December 4, 2023
Truqap (capivasertib) plus Faslodex approved in the US for patients with advanced HR-positive breast cancer December 4, 2023
Completion of the Safety Lead-In and Opening of Ph 2 of the AIPAC-003 Ph 2/3 Trial in Metastatic Breast Cancer Announced November 7, 2023
Fast Track Designation for IDE161 for the Treatment of Pretreated, Advanced or Metastatic HR+, HER2-, BRCA1/2 mutant Breast Cancer October 3, 2023
Datopotamab deruxtecan demonstrated statistically significant PFS benefit in patients with HR+ve, HER2-low/neg breast cancer in TROPION-Breast01 Ph 3 trial September 26, 2023
European Commission Approves ORSERDU in Patients with ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer September 26, 2023
Ph 3 KEYNOTE-756 Trial Met Primary Endpoint of pCR Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer August 2, 2023
European Commission Approves Trodelvy For Pre-Treated HR+/HER2- Metastatic Breast Cancer August 2, 2023
Positive CHMP Opinion to ORSERDU® (Elacestrant) for ER+, HER2-, ESR1-mutated Locally Advanced or Metastatic Breast Cancer patients July 22, 2023
Eisai Transfers All Future Economic Rights for Elacestrant, a Selective Estrogen Receptor Degrader, to DRI Healthcare July 19, 2023
Capivasertib in combination with Faslodex granted Priority Review in the US for patients with advanced HR-positive breast cancer June 21, 2023
Kisqali® Ph 3 NATALEE Trial Meets Primary Endpoint At Interim Analysis Demonstrating Clinically Meaningful Benefit In Patients With Early Breast Cancer March 31, 2023
First Patient dosed in Ph 2 Neoadjuvant Clinical Study of (Z)-Endoxifen in Premenopausal Women with ER+/HER2- Breast Cancer February 28, 2023
